Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Media Influence and Body Image in 8-11 Year Old Boys and Girls: A Preliminary Report on the Multidimensional Media Influence Scale

Objective: To develop a scale for the assessment of multiple components of a media‐based influence on body image. Method: Seventy‐five boys and 107 girls, ranging in age from 8 to 11, completed a measure designed to assess five facets of a media influence previously conceptualized by researchers. Results: Three distinct scales emerged, which appeared to focus on concepts defined as internalization, awareness, and pressure. Correlations between subscales of the Multidimensional Media Influence Scale (MMIS) and the Eating Disorder Inventory‐Body Dissatisfaction subscale were significant for both boys and girls. Girls had higher levels on all three subscales and regression analyses indicated that the MMIS scores predicted 30% of the variance associated with body dissatisfaction for girls, but an R2 of only .10 emerged for boys. Internalization levels predicted significant variance beyond that explained by awareness and pressures, but only for the female sample. Discussion: The findings are discussed with regard to the usefulness of the MMIS for future research and the role of internalization as a risk factor for the development of body image disturbances and eating disorders

Introducing the CTA concept

The Cherenkov Telescope Array (CTA) is a new observatory for very high-energy (VHE) gamma rays. CTA has ambitions science goals, for which it is necessary to achieve full-sky coverage, to improve the sensitivity by about an order of magnitude, to span about four decades of energy, from a few tens of GeV to above 100 TeV with enhanced angular and energy resolutions over existing VHE gamma-ray observatories. An international collaboration has formed with more than 1000 members from 27 countries in Europe, Asia, Africa and North and South America. In 2010 the CTA Consortium completed a Design Study and started a three-year Preparatory Phase which leads to production readiness of CTA in 2014. In this paper we introduce the science goals and the concept of CTA, and provide an overview of the project. © 2013 Elsevier B.V. All rights reserved

Cherenkov Telescope Array Contributions to the 35th International Cosmic Ray Conference (ICRC2017)

List of contributions from the Cherenkov Telescope Array Consortium presented at the 35th International Cosmic Ray Conference, July 12-20 2017, Busan, Korea.Comment: Index of Cherenkov Telescope Array conference proceedings at the ICRC2017, Busan, Kore

Introducing the CTA concept

The Cherenkov Telescope Array (CTA) is a new observatory for very high-energy (VHE) gamma rays. CTA has ambitions science goals, for which it is necessary to achieve full-sky coverage, to improve the sensitivity by about an order of magnitude, to span about four decades of energy, from a few tens of GeV to above 100 TeV with enhanced angular and energy resolutions over existing VHE gamma-ray observatories. An international collaboration has formed with more than 1000 members from 27 countries in Europe, Asia, Africa and North and South America. In 2010 the CTA Consortium completed a Design Study and started a three-year Preparatory Phase which leads to production readiness of CTA in 2014. In this paper we introduce the science goals and the concept of CTA, and provide an overview of the project

CTA contributions to the 33rd International Cosmic Ray Conference (ICRC2013)

Compilation of CTA contributions to the proceedings of the 33rd International Cosmic Ray Conference (ICRC2013), which took place in 2-9 July, 2013, in Rio de Janeiro, BrazilComment: Index of CTA conference proceedings at the ICRC2013, Rio de Janeiro (Brazil). v1: placeholder with no arXiv links yet, to be replaced once individual contributions have been all submitted. v2: final with arXiv links to all CTA contributions and full author lis

CTA Contributions to the 34th International Cosmic Ray Conference (ICRC2015)

List of contributions from the CTA Consortium presented at the 34th International Cosmic Ray Conference, 30 July - 6 August 2015, The Hague, The Netherlands.Comment: Index of CTA conference proceedings at the ICRC2015, The Hague (The Netherlands). v1: placeholder with no arXiv links yet, to be replaced once individual contributions have been all submitted; v2: final with arXiv links to all CTA contributions and full author lis